PHOENIX, AZ, OncoMyx Therapeutics, a privately-held immuno-oncology platform company, announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors: Boehringer Ingelheim Venture Fund, Delos Capital, Xeraya Capital, Korea Investment Partners, City Hill Ventures, and Madison Partners.

OncoMyx Therapeutics, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement. The company's MYXV platform, spun out from ASU, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.